AstraZeneca shares fell on Monday even after the publication of positive results from a trial of its experimental COVID-19 vaccine developed in partnership with Oxford University.
The study, published in The Lancet on Monday, said healthy volunteers who received the experimental vaccine, called AZD1222, showed immune responses.
Last week, The Daily Telegraph reported that blood samples of volunteers in the trial showed both antibodies and T cells.
AstraZeneca said in June that it would supply up to 2 billion doses of the vaccine worldwide.
Comments are closed.